Engineered proteins pull double duty.
Myriad bi-specific proteins have been developed that recognize two different clinical targets, with the goal of achieving enhanced therapeutic effects as compared with proteins that interact with only one target. These engineered proteins are starting to enter clinical testing for a variety of biomedical applications, particularly cancer treatment.
Cochran
Jennifer R
JR
Department of Bioengineering, Cancer Center, Bio-X Program, Stanford University, Stanford, CA 94305-5439, USA. jennifer.cochran@stanford.edu
D000818:Animals; D018033:Antibodies, Bispecific / Q000737:chemistry; D001709:Biotechnology / Q000379:methods; D016207:Cytokines / Q000737:chemistry; D000939:Epitopes / Q000737:chemistry; D006801:Humans; D008024:Ligands; D051379:Mice; D015202:Protein Engineering / Q000379:methods*; D011506:Proteins / Q000737:chemistry*; D051381:Rats
D018033:Antibodies, Bispecific; D016207:Cytokines; D000939:Epitopes; D008024:Ligands; D011506:Proteins